About the Lab
Our lab's research interests focus on cell therapy for viral and malignant diseases. Led by Catherine Bollard, M.D., M.B.Ch. B., we are running clinical trials assessing the safety of adoptively transferred, virus-specific T cells for the prevention and treatment of viral infection including after allogeneic stem cell and cord blood transplant, as well as for the treatment of virus-associated malignancies such as EBV and HIV.
Most recently, the team has focused on targeting multiple viruses including HHV6, BK virus, CMV, adenovirus, parainfluenza, norovirus and most recently the coronavirus SARS-Cov2. In addition, we are investigating the utility of this approach using genetically modified cell therapies (NK cells and T cells) for blood cancers and solid tumors. We also are evaluating the efficacy of tumor-specific T cells for patients with leukemia and lymphoma and pediatric solid tumors. Further, we are interested in novel strategies to target the cancer stem cell and to counteract tumor immune evasion mechanisms to enhance the efficacy of adoptive immunotherapy protocols.
SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane proteinKeller MD, Harris KM, Jensen-Wachspress MA, Kankate VV, Lang H, Lazarski CA, Durkee-Shock J, Lee PH, Chaudhry K, Webber K, Datar A, Terpilowski M, Reynolds EK, Stevenson EM, Val S, Shancer Z, Zhang N, Ulrey R, Ekanem U, Stanojevic M, Geiger A, Liang H, Hoq F, Abraham AA, Hanley PJ, Cruz CR, Ferrer K, Dropulic L, Gangler K, Burbelo PD, Jones RB, Cohen JI, Bollard CM PMID: 33331927. Free PMC article. Blood 136(25):2905-2917. doi: 10.1182/blood.2020008488 December (2020)
Successful outcomes of newly diagnosed T lymphoblastic lymphoma: Results from Children's Oncology Group AALL0434Hayashi RJ, Winter SS, Dunsmore KP, Devidas M, Chen Z, Wood BL, Hermiston ML, Teachey DT, Perkins SL, Miles RR, Raetz EA, Loh ML, Winick NJ, Carroll WL, Hunger SP, Lim MS, Gross TG, Bollard CM PMID: 32552472 Clinical Trial J Clin Oncol 38(26):3062-3070. doi: 10.1200/JCO.20.00531. Epub June (2020)
Immunotherapy of relapsed and refractory solid tumors with ex vivo expanded multi-tumor associated antigen specific cytotoxic T lymphocytes: A phase I studyHont AB, Cruz CR, Ulrey R, O'Brien B, Stanojevic M, Datar A, Albihani S, Saunders D, Hanajiri R, Panchapakesan K, Darko S, Banerjee P, Fortiz MF, Hoq F, Lang H, Wang Y, Hanley PJ, Dome JS, Bollard CM, Meany HJ PMID: 31356143 Free PMC article. Clinical Trial. J Clin Oncol 37(26):2349-2359. doi: 10.1200/JCO.19.00177. Epub July (2019)
Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipientsAbraham AA, John TD, Keller MD, Cruz CRN, Salem B, Roesch L, Liu H, Hoq F, Grilley BJ, Gee AP, Dave H, Jacobsohn DA, Krance RA, Shpall EJ, Martinez CA, Hanley PJ, Bollard CM PMID: 31292125 Free PMC article. Blood Adv 3(14):2057-2068. doi: 10.1182/bloodadvances.2019000201 July (2019)
Engineering the TGFβ Receptor to enhance the therapeutic potential of natural killer cells as an immunotherapy for neuroblastomaBurga RA, Yvon E, Chorvinsky E, Fernandes R, Cruz CRY, Bollard CM PMID: 31010834 Free PMC article. Clin Cancer Res 25(14):4400-4412. doi: 10.1158/1078-0432.CCR-18-3183. Epub April (2019)